CORCEPT THERAPEUTICS INC 4

Chief Accounting & Technology Officer Joseph Douglas Lyon sold 1,540 shares of Corcept Therapeutics Inc. common stock at $114.16 per share and now holds 5,495 shares.

On August 3, 2026, Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics Inc., sold 1,540 shares of the company’s common stock at an average price of $114.16 per share, for estimated proceeds of about $175,800. Following this disposition, he directly owns 5,495 shares, which include both vested holdings and 1,313 shares underlying multiple unvested restricted stock awards that will vest in full on the one-year anniversary of their respective grant dates, subject to service conditions. Based on the reported transaction price as a proxy for the current market price, his post-transaction equity stake is valued at approximately $627,800, indicating that this was a moderate-sized insider sale rather than a complete reduction in his position.

Filing Facts

CIK

1088856

Ticker

CORT

Form

4

Source Type

fda

Accession

0001193125-26-335605

Alert Tier

6